79491-45-5

Basic information

• Product Name: 2,6-dibroMo-3-Methoxypyridine
• Synonyms: 2,6-dibroMo-3-Methoxypyridine
• CAS NO: 79491-45-5
• Molecular Formula: C₆H₅Br₂NO
• Molecular Weight: 266.918
• Product Categories: alkyl bromide
• Mol File: 79491-45-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 99-100 °C(Solv: hexane (110-54-3))
• Boiling Point: 294.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.919±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -7.50±0.10(Predicted)
• CAS DataBase Reference: 2,6-dibroMo-3-Methoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dibroMo-3-Methoxypyridine(79491-45-5)
• EPA Substance Registry System: 2,6-dibroMo-3-Methoxypyridine(79491-45-5)

Safety Data

• Hazardous Substances Data: 79491-45-5(Hazardous Substances Data)

Usage

General Description

2,6-dibromo-3-methoxypyridine is a specialized chemical compound that belongs to the group of organic compounds known as Pyridines and derivatives. As the name suggests, it has two bromine atoms and one methoxy group attached to the pyridine ring. 2,6-dibroMo-3-Methoxypyridine has a molecular formula of C6H5Br2NO, indicating that each molecule of 2,6-dibromo-3-methoxypyridine consists of six carbon atoms, five hydrogen atoms, two bromine atoms, one nitrogen atom, and one oxygen atom. Its molecular weight is around 286.92 g/mol. This substance is heavily used in various chemical syntheses and reactions due to its properties and structure. Additionally, it is commonly used as a reagent in the field of pharmaceuticals and agriculture. It should be handled with care as exposure may cause irritation to the eyes, skin, and respiratory system.

Upstream product

• 6602-33-1 2,6-dibromopyridin-3-ol 
• 74-88-4 methyl iodide 
• 109-00-2 3-HYDROXYPYRIDINE 

Downstream Products

• 79491-46-6 2,6-dibromo-3-methoxy-5-nitropyridine 
• 64436-92-6 3-amino-5-methoxypyridine 
• 79491-49-9 3-amino-5,6-dimethoxypyridine 
• 79491-47-7 2,6-dibromo-5-methoxypyridin-3-amine 
• 79491-48-8 2-bromo-5,6-dimethoxy-3-nitropyridine 
• 1438286-74-8 2-bromo-3-methoxy-6-(1-(3,4,5-trimethoxyphenyl)vinyl)pyridine 
• 138323-94-1 3-methoxypyridine-2,6-diamine 
• 86271-56-9 (E)-2,6-diamino-5-(phenyldiazenyl)pyridin-3-ol 

Relevant articles and documents

COMPOUNDS USEFUL TO TREAT PAIN

The present invention relates to compounds useful as bradykinin receptor antagonist, pharmaceutical composition comprising such compounds, and therapeutic use of the same. The present invention further relates to the combination of compounds useful for the therapeutic use. The present invention relates to the pharmaceutical composition comprising the compound and combination of compounds useful for treatment of urinary bladder pain, the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.

HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The invention relates to a novel heterocyclic compound inhibiting a cyclin-dependent kinase (CDK) and a pharmaceutical composition comprising the same as an effective ingredient. The heterocyclic compound according to the present invention or pharmaceutically acceptable salt thereof can be effectively used in treating or preventing cancers, degenerative brain diseases, etc.

Phosphoinositide-3-kinase inhibitors: Evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511

Replacement of the piperazine sulfonamide portion of the PI3Kα inhibitor AMG 511 (1) with a range of aliphatic alcohols led to the identification of a truncated gem-dimethylbenzylic alcohol analog, 2-(5-(4-amino-6-methyl-1,3,5-triazin-2-yl)-6-((5-fluoro-6-methoxypyridin-3-yl)amino)pyridin-3-yl)propan-2-ol (7). This compound possessed good in vitro efficacy and pharmacokinetic parameters and demonstrated an EC50 of 239 ng/mL in a mouse liver pharmacodynamic model measuring the inhibition of hepatocyte growth factor (HGF)-induced Akt Ser473 phosphorylation in CD1 nude mice 6 h post-oral dosing.